Modified drug release refers to the strategic alteration of the release kinetics of a pharmaceutical compound within the body, aiming to optimize therapeutic outcomes while minimizing adverse effects. This approach encompasses a variety of techniques and formulations designed to exert control over the timing, rate, and location of drug delivery. One common strategy involves the development of sustained-release formulations, where the drug is released gradually over an extended period, maintaining therapeutic concentrations in the bloodstream and thereby reducing the frequency of dosing. These formulations often employ specialized drug delivery systems such as hydrogels, liposomes, or microspheres, which encapsulate the active ingredient and control its release through diffusion, erosion, or other mechanisms.
Another approach to modified drug release involves targeting specific sites or tissues within the body to enhance efficacy and reduce systemic side effects. This can be achieved through the use of targeted drug delivery systems that exploit physiological or pathological characteristics of the target tissue, such as pH, temperature, or enzymatic activity. By encapsulating the drug within carriers that selectively release their cargo in response to these cues, researchers can achieve site-specific drug delivery, maximizing therapeutic effects while minimizing off-target effects.
In addition to sustained-release and targeted delivery approaches, modified drug release can also involve the use of novel drug delivery routes and technologies. For example, transdermal patches and implants allow for continuous and controlled release of drugs through the skin or implanted devices, offering advantages such as improved patient compliance and reduced dosing frequency. Similarly, advances in nanotechnology have enabled the development of nanoscale drug delivery systems capable of crossing biological barriers and delivering drugs to specific cellular targets, opening up new possibilities for personalized medicine and precision therapeutics.
Title : Advances in plasma-based waste treatment for sustainable communities
Hossam A Gabbar, Ontario Tech University, Canada
Title : Nanostructured biodevices based on carbon nanotubes and glyconanoparticles for bioelectrocatalytic applications
Serge Cosnier, Silesian University of Technology, Poland
Title : Carbon capture and storage: The impact of impurities in CO2 streams
Andy Brown, Progressive Energy Ltd, United Kingdom
Title : Supramolecular nano chemistries: Fighting viruses, inhibiting bacteria and growing tissues
Thomas J Webster, Hebei University of Technology, China
Title : Chemical engineering of vanadium and tantalum zeolites for application in environmental catalysis
Stanislaw Dzwigaj, Sorbonne Universite, France
Title : Disrupting TNF-α and TNFR1 interaction: Computational insights into the potential of D-Pinitol as an anti-inflammatory therapeutic
Ferran Acuna Pares, Universidad Internacional de la Rioja (UNIR), Spain